WNK2 and neurofibromatosis type 1: Given that preclinical trials of Ras–mitogen-activated protein kinase (MAPK) inhibitors, lovastatin and simvastatin, failed to improve learning and attention deficits in children with NF1 [56,57], cAMP signaling enhancement strategies may be a promising avenue for ameliorating the cognitive dysfunction in NF1.